Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study - PubMed This study demonstrated that patients prefer adjuvant treatment with higher efficacy and lower risk of adverse events. These data will aid shared decision-making when discussing the addition of CDK4/6...

A survey showed pts with early-stage #breastcancer placed ⬆️ importance on efficacy and ⬇️ risk of symptomatic adverse events over other attributes when making treatment choices in the adjuvant setting.
pubmed.ncbi.nlm.nih.gov/39915434/
@maryamlustberg.bsky.social @yaleschoolofmed.bsky.social

The Wowdhari kids are doing great…medals for everyone at their last competitions: volleyball for Asha and gymnastics for Casey! 💪🏽👍🏼

The Wowdhari kids are doing great…medals for everyone at their last competitions: volleyball for Asha and gymnastics for Casey! 💪🏽👍🏼

link.springer.com/content/pdf/...